The decrease in CD163 mRNA was confirmed by IHC in all samples (Fig. S7c) and a set of paired samples where a baseline biopsy from the lung had ~7% of the tumor area positive for CD163 compared to ~1% in a biopsy from the same lesion at progression (Day 125) (Fig. 6b). Here, CD163 is linked to neoplasm.